08 . 07 .2025
News story
Scratching the Surface: shedding light on a misunderstood skin disease
25 . 06 .2025
Press release
Galderma initiates two new clinical trials investigating nemolizumab in patients with Systemic Sclerosis and Chronic Pruritus of Unknown Origin
18 . 06 .2025
Press release
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years
17 . 06 .2025
Press release
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership
06 . 06 .2025
News story
Revolutionizing Atopic Dermatitis 2025 Conference: Galderma’s Scientific Presentations
06 . 06 .2025
Press release
RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years
05 . 06 .2025
News story
International Congress of Dermatology 2025: Galderma’s Scientific Presentations